Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival

By Heys Steven  

Breast Cancer Research and Treatment, Vol. 90, Iss. 2, 2005-03 ,pp. : 169-185

Springer Publishing Company

Access to resources Recommend Favorite

Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study

By Mansi Janine   Yellowlees Ann   Lipscombe Julian   Earl Helena   Cameron David   Coleman Robert   Perren Timothy   Gallagher Christopher   Quigley Mary   Crown John   Jones Alison   Highley Martin   Leonard Robert   Jeffry Evans T.  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 787-794

Springer Publishing Company

Access to resources Recommend Favorite

The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer

By Cocquyt Veronique   Schelfhout Vera   Blondeel Phillip   Depypere Herman   Daems Kristof   Serreyn Rudolphe   Praet Marleen   Beele Simon  

Medical Oncology, Vol. 20, Iss. 3, 2003-09 ,pp. : 221-231

Humana Press, Inc

Access to resources Recommend Favorite

Receptor-based predictors of response in breast cancer

By McGovern Ursula B   Stebbing Justin  

Future Oncology, Vol. 5, Iss. 3, 2009-04 ,pp. : 283-286

Future Medicine

Access to resources Recommend Favorite

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

By Cooper Brenda   Radivoyevitch Tomas   Overmoyer Beth   Shenk Robert   Pham Huong   Samuels Judith   Parry Margaret   Silverman Paula  

Breast Cancer Research and Treatment, Vol. 97, Iss. 3, 2006-06 ,pp. : 311-318

Springer Publishing Company

Access to resources Recommend Favorite